This bsAb did not outperform a combination of CD47 mAb and RTX treatment in terms of inhibition of tumour (Raji) growth in NSG mice, although the impact of the ‘CD47 antigen sink’ was not evaluated, as the bsAb did not cross‐react with mouse CD47.47 A phase I clinical trial with this bsAb is recruiting (CTR20192612). Here, CD47 is linked to neoplasm.